Emergex Announces Positive Phase I Trial Data for DengueTcP™, Its Novel T Cell-Priming Immune Set-Point Candidate
06 juin 2023 11h45 HE
|
Emergex Vaccines Holding Ltd
naNO-DENGUE trial results demonstrate that DengueTcP is well-tolerated with no treatment-related serious adverse events Immunogenicity data shows peptide antigen-specific effector and memory CD8+...
Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine
28 nov. 2022 07h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine Peptides specific to Chikungunya (CHIKV) virus expressed on surfaces of infected...
Emergex Confirms Synthesis of a CD8+ T cell Adaptive Vaccine for Smallpox and Monkeypox
18 oct. 2022 07h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Confirms Synthesis of a CD8+ T cell Adaptive Vaccine for Smallpox and Monkeypox Vaccine construct comprised predominantly of peptides from early “eclipse phase” antigens...
Emergex Acquires Intradermal and Patch Drug Delivery Technology with Its Manufacturing Equipment from Zosano Pharma
12 oct. 2022 07h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Acquires Intradermal and Patch Drug Delivery Technology with Its Manufacturing Equipment from Zosano Pharma Abingdon, Oxon, UK, 12 October 2022 – Emergex Vaccines Holding...
Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine
28 juil. 2022 02h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine Emergex will manufacture the candidate universal influenza vaccine to cGMP standards for use in Phase I...
Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil
01 juil. 2022 02h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil Abingdon, Oxon, UK, 1 July 2022 – Emergex Vaccines Holding Limited...
Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch
17 mai 2022 07h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch Emergex’s COVID-19 and Dengue CD8+ T cell...
Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines
18 avr. 2022 02h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines Both studies fully recruited, with data from the Dengue Fever...
Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives
14 avr. 2022 02h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives Emergex’s CD8+ T cell Adaptive Vaccine...
Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate
07 avr. 2022 02h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate Abingdon, Oxon, UK, 7 April 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or...